Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) and Precigen (NASDAQ:PGEN – Get Free Report) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, profitability, valuation and institutional ownership.
Valuation & Earnings
This table compares Celldex Therapeutics and Precigen”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Celldex Therapeutics | $158,000.00 | 19,164.80 | -$258.76 million | ($4.35) | -8.86 |
| Precigen | $9.68 million | 289.70 | -$250.64 million | ($1.04) | -7.56 |
Analyst Recommendations
This is a summary of recent recommendations and price targets for Celldex Therapeutics and Precigen, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Celldex Therapeutics | 1 | 1 | 10 | 1 | 2.85 |
| Precigen | 1 | 0 | 3 | 1 | 2.80 |
Celldex Therapeutics presently has a consensus target price of $56.42, suggesting a potential upside of 46.31%. Precigen has a consensus target price of $14.50, suggesting a potential upside of 84.34%. Given Precigen’s higher possible upside, analysts clearly believe Precigen is more favorable than Celldex Therapeutics.
Institutional & Insider Ownership
33.5% of Precigen shares are owned by institutional investors. 5.2% of Celldex Therapeutics shares are owned by insiders. Comparatively, 41.4% of Precigen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Risk and Volatility
Celldex Therapeutics has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Comparatively, Precigen has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500.
Profitability
This table compares Celldex Therapeutics and Precigen’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Celldex Therapeutics | N/A | -52.35% | -47.61% |
| Precigen | -183.98% | 423.75% | 84.39% |
Summary
Precigen beats Celldex Therapeutics on 10 of the 14 factors compared between the two stocks.
About Celldex Therapeutics
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company’s clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
About Precigen
Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
